VanEck Associates
BEAM icon

VanEck Associates’s Beam Therapeutics BEAM Stock Holding History

VanEck Associates’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69K Sell
2,884
-1,035
-26% -$28.7K ﹤0.01% 1322
2025
Q4 		$109K Buy
3,919
+1,761
+82% +$44.9K ﹤0.01% 1319
2025
Q3 		$52K Buy
2,158
+707
+49% +$14.1K ﹤0.01% 1343
2025
Q2 		$25K Buy
1,451
+147
+11% +$2.56K ﹤0.01% 1348
2025
Q1 		$25K Buy
1,304
+316
+32% +$8.28K ﹤0.01% 1330
2024
Q4 		$25K Buy
988
+138
+16% +$3.52K ﹤0.01% 1329
2024
Q3 		$19K Sell
850
-190
-18% -$4.91K ﹤0.01% 1315
2024
Q2 		$24K Sell
1,040
-105
-9% -$2.58K ﹤0.01% 1320
2024
Q1 		$38K Hold
1,145
– – ﹤0.01% 1293
2023
Q4 		$31K Buy
1,145
+57
+5% +$1.42K ﹤0.01% 1310
2023
Q3 		$26K Hold
1,088
– – ﹤0.01% 1323
2023
Q2 		$35K Hold
1,088
– – ﹤0.01% 1320
2023
Q1 		$33K Sell
1,088
-36
-3% -$1.42K ﹤0.01% 1332
2022
Q4 		$44K Buy
1,124
+408
+57% +$18.3K ﹤0.01% 1322
2022
Q3 		$34K Buy
+716
New +$40.8K ﹤0.01% 1291

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

VanEck Associates's BEAM Position: Q1 2026 in Review

VanEck Associates reduced its Beam Therapeutics (BEAM) stake by 26% in Q1 2026, selling an estimated $28.7K and leaving 2,884 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #1322.

VanEck Associates first reported a position in BEAM in Q3 2022 and has held it in 15 quarters since. The position peaked at $109K in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • VanEck Associates held 2,884 shares of Beam Therapeutics worth $69K as of Q1 2026.
  • VanEck Associates sold 1,035 Beam Therapeutics shares in Q1 2026, an estimated $28.7K.
  • Beam Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #1322 holding.
  • VanEck Associates first reported a position in Beam Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • VanEck Associates's Beam Therapeutics position peaked at $109K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.